In ovo administration of Toll-like receptor ligands encapsulated in PLGA nanoparticles impede tumor development in chickens infected with Marek’s disease virus
Abstract
No abstract availableKeywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada
- Ministry of Agriculture, Food and Agribusiness
This publication has 43 references indexed in Scilit:
- Interleukin-18 and IL-18 Binding ProteinFrontiers in Immunology, 2013
- A Toll-Like Receptor 3 Ligand Enhances Protective Effects of Vaccination Against Marek's Disease Virus and Hinders Tumor Development in ChickensViral Immunology, 2012
- In vivo administration of ligands for chicken toll-like receptors 4 and 21 induces the expression of immune system genes in the spleenVeterinary Immunology and Immunopathology, 2011
- Type I Interferon Contributes to CD4+T Cell Depletion Induced by Infection with HIV-1 in the Human ThymusJournal of Virology, 2011
- The pharmacokinetics of Toll-like receptor agonists and the impact on the immune systemExpert Review of Clinical Pharmacology, 2011
- Recognition of herpesviruses by the innate immune systemNature Reviews Immunology, 2011
- Effects of Lactobacilli on Cytokine Expression by Chicken Spleen and Cecal Tonsil CellsClinical and Vaccine Immunology, 2010
- TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumoursOncogene, 2008
- CpG oligonucleotide activates Toll-like receptor 9 and causes lung inflammation in vivoRespiratory Research, 2007
- Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR InhibitorsClinical Cancer Research, 2006